Persistent Orodental Pain, Atypical Odontalgia, and Phantom Tooth Pain: When Are They Neuropathic Disorders?

Clark, Glenn T.

doi:10.1080/19424396.2006.12222229

Cited by 39 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In all COP patients, the severity of pain and depressive symptoms were assessed using the Visual Analog Scale (VAS) 26 and 17-item Hamilton Depression Rating Scale (HDRS), 24 respectively, before and after 12 weeks of DLX treatment by psychiatrists. All COP patients were classified into COP patients with depressive symptoms (COP-D: HDRS score $ 8) and without depressive symptoms (COP-ND: HDRS score , 8) based on their HDRS scores before DLX treatment by following the previous report: no depression (0-7), mild depression (8)(9)(10)(11)(12)(13)(14)(15)(16), moderate depression (17)(18)(19)(20)(21)(22)(23), and severe depression ($24) in a large study of major depressive disorder (MDD) patients. 76…”

Section: Clinical Assessmentmentioning

confidence: 99%

“…51 Since these diseases are diagnosed after excluding other organic disorders, 17,21,40,56,63,70 it takes time to determine a definitive diagnosis. 11,41 Chronic orofacial pain such as BMS and PIFP significantly impairs patients' quality of life. In pain clinics and inpatient pain programs, about 52% of patients with pain are reported to have comorbid depression.…”

Section: Introductionmentioning

confidence: 99%

“…51 Since these diseases are diagnosed after excluding other organic disorders, 17,21,40,56,63,70 it takes time to determine a definitive diagnosis. 11,41…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Duloxetine improves chronic orofacial pain and comorbid depressive symptoms in association with reduction of serotonin transporter protein through upregulation of ubiquitinated serotonin transporter protein

Nakamura,

Yoshimi,

Tokura

et al. 2024

Pain

View full text Add to dashboard Cite

Chronic orofacial pain (COP) is relieved by duloxetine (DLX) and frequently causes depressive symptoms. The aim of this study was to confirm effects of DLX on pain and depressive symptoms, and to associate with their effectiveness in platelet serotonin transporter (SERT) expression, which is a target molecule of DLX and plasma serotonin concentration in COP patients with depressive symptoms. We assessed for the severity of pain and depressive symptoms using the Visual Analog Scale (VAS) and 17-item Hamilton Depression Rating Scale (HDRS), respectively. Chronic orofacial pain patients were classified into 2 groups based on their HDRS before DLX-treatment: COP patients with (COP-D) and without (COP-ND) depressive symptoms. We found that the VAS and HDRS scores of both groups were significantly decreased after DLX treatment compared with those before DLX treatment. Upregulation of total SERT and downregulation of ubiquitinated SERT were observed before DLX treatment in both groups compared with healthy controls. After DLX treatment, there were no differences in total SERT of both groups and in ubiquitinated SERT of COP-D patients compared with healthy controls; whereas, ubiquitinated SERT of COP-ND patients remained downregulated. There were positive correlations between changes of serotonin concentrations and of VAS or HDRS scores in only COP-D patients. Our findings indicate that DLX improves not only pain but also comorbid depressive symptoms of COP-D patients. Duloxetine also reduces platelet SERT through upregulation of ubiquitinated SERT. As the result, decrease of plasma serotonin concentrations may be related to the efficacy of DLX in relieving pain and depression in COP patients.

show abstract

Section: Clinical Assessmentmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Duloxetine improves chronic orofacial pain and comorbid depressive symptoms in association with reduction of serotonin transporter protein through upregulation of ubiquitinated serotonin transporter protein

Nakamura,

Yoshimi,

Tokura

et al. 2024

Pain

View full text Add to dashboard Cite

show abstract

“…The orofacial region is a very complex region from an anatomical point of view. It houses an enormous breadth of structures, and each of them has very complex vasculature and equally complicated innervation [39].…”

Section: Orofacial Painmentioning

confidence: 99%

Orofacial Pain and Dentistry Management: Guidelines for a More Comprehensive Evidence-Based Approach

Labanca,

Gianò,

Franco

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Orofacial pain represents one of the most common health problems that negatively affects the activities of daily living. However, the mechanisms underlying these conditions are still unclear, and their comprehensive management is often lacking. Moreover, even if pain is a common symptom in dentistry, differential diagnostic procedures are needed to exclude other pain origins. Misinterpretation of the pain origin, in fact, can lead to misdiagnosis and to subsequent mismanagement. Pain in the orofacial area is the most common reason for patients to visit the dentist, but this area is complex, and the pain could be associated with the hard and soft tissues of the head, face, oral cavity, or to a dysfunction of the nervous system. Considering that the origins of orofacial pain can be many and varied, a thorough assessment of the situation is necessary to enable the most appropriate diagnostic pathway to be followed to achieve optimal clinical and therapeutic management.

show abstract

“…Later, Marbach and Raphael [33] described PTP as a deafferentation pain disorder in teeth that have been denervated by removal or pain in the area formerly occupied by teeth prior to their extraction. Other experts strictly define PTP as unexplained persistent pain at the site of an extracted tooth [34].…”

Section: Phantom Tooth Pain [Ptp]mentioning

confidence: 99%

Crosstalk between Mind and Oral Cavity: An Insight into Pathogenesis, Classification, Presentation and Management of Oral Psychosomatic Disorders

Jain

Mehendiratta²,

Kardam³

et al. 2016

INDJ

View full text Add to dashboard Cite

In general, the conviction is that psychological factors are important in the development of all disease. Epidemiological surveys have revealed that there are different ways in which emotional stressful stimuli can act on oral mucosal target sites. Whether their role is in initiation, progression, aggravation or exacerbation of disease or in predisposition or reaction to a disease is still not clear. Based on available evidences, a need for the understanding of oral psychosomatic disturbances is felt. This review summarizes the underlying pathophysiology of bodily changes brought about by stress related psychosomatic mechanism and their role in further development of structural changes seen in association with oral cavity. An effort has also been made to realize the significant Review Article role of reassurance and counselling procedures in overall management of patients with oral psychosomatic disorders.

show abstract

Persistent Orodental Pain, Atypical Odontalgia, and Phantom Tooth Pain: When Are They Neuropathic Disorders?

Cited by 39 publications

References 30 publications

Duloxetine improves chronic orofacial pain and comorbid depressive symptoms in association with reduction of serotonin transporter protein through upregulation of ubiquitinated serotonin transporter protein

Duloxetine improves chronic orofacial pain and comorbid depressive symptoms in association with reduction of serotonin transporter protein through upregulation of ubiquitinated serotonin transporter protein

Orofacial Pain and Dentistry Management: Guidelines for a More Comprehensive Evidence-Based Approach

Crosstalk between Mind and Oral Cavity: An Insight into Pathogenesis, Classification, Presentation and Management of Oral Psychosomatic Disorders

Contact Info

Product

Resources

About